Means they are missing some pre clinical data and they have 2-3 months to resubmit and why AGN submitted it early before phase 2 read out to deal with these minor issues along the way. Could be a reason that they are in talks with China firms for a licensing agreement to fast track it there with a bigger market potential
Don’t like glutamate receptors, FDA never has
Means they are missing some pre clinical data and they have 2-3...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
67.0¢ |
Change
-0.010(1.47%) |
Mkt cap ! $86.06M | |||
| Open | High | Low | Value | Volume |
| 68.0¢ | 68.0¢ | 66.5¢ | $37.30K | 55.36K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10760 | 66.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 67.0¢ | 33 | 1 |
View Market Depth
| Last trade - 16.10pm 01/08/2025 (20 minute delay) ? |
| AGN (ASX) Chart |